BioSyent Releases Results for Fourth Quarter and Full Year 2017
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) released today a summary of its financial results for the three and twelve months ended December 31, 2017. Key highlights include: Fourth quarter (Q4) 2017 Net Revenues of $5,901,488 increased by 18% versus Q4 2016 Full Year (FY) 2017 Net Revenues of $20,762,755 increased by 16% versus FY 2016 Q4 2017 Canadian Pharmaceutical Net Revenues of $4,937,297 increased by 12% versus Q4 2016 and International Pharmaceutical Net Revenues of $868,917 increased by 75% versus Q4 2016 FY 2017 Canadian Pharmaceutical Net Revenues of $16,856,703 increased by 12% versus FY 2016 and International Pharmaceutical Net Revenues of $2,476,902 increased by 60% versus FY 2016 Q4 2017 EBITDA 1 of $1,961,159 increased by 23% versus Q4 2016 FY 2017 EBITDA 1 of $6,910,977 increased by 17% versus FY 2016 Q4 2017 Net Income After Tax (NIAT) of $1,457,228 increased by 33% versus Q4 2016 FY 2017 NIAT of $5,206,277 incr